徳島大学 教育・研究者情報データベース(EDB)

1. (英) Wu Qishisan

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. 原田 永勝

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Nakamura Aki

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Yoshida Masaki

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. 馬渡 一諭

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. (英) Hattori Atsushi

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Li Qinkai

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. (英) Shimohata Takaaki

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Yinhua

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Lian Xin

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. (英) Nakano Masayuki

    役割	任意
    貢献度	任意
    学籍番号	推奨

12. 保坂 利男

    役割	任意
    貢献度	任意
    学籍番号	推奨

13. 髙橋 章([徳島大学.大学院医歯薬学研究部.医学域.栄養科学部門.医科栄養学系.予防環境栄養学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

14. 中屋 豊

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) NO-1886, a lipoprotein lipase activator, attenuates contraction of rat intestinal ring preparations

(英) Various intestinal symptoms or diseases are closely associated with intestinal motility, which may be altered by metabolic disturbances associated with diabetes and obesity. It is therefore important that drugs used in the treatment of metabolic disorders should not have any adverse effects on the intestine. In the present study, we examined whether [4-(4-bromo-2-cyano-phenylcarbamoyl)-benzyl]-phosphonic acid diethyl ester (NO-1886), a lipoprotein lipase activator with anti-diabetic and/or anti-obese activity, affects stimulant-induced intestinal contractility. Administration of NO-1886 to intestinal ring preparations of ileum, rectum and colon isolated from Wistar rats attenuated or relaxed contraction induced by a high K+ environment or acetylcholine (ACh). This effect of NO-1886 was dependent on extracellular Ca(2+) and intracellular myosin light chain kinase activity. Our results also showed that ACh-induced colonic contraction was significantly higher in the obese Otsuka Long-Evans Tokushima Fatty (OLETF) than in the non-obese Long-Evans Tokushima Otsuka (LETO) rats. The hypercontractility observed in the colons of OLETF rats occurred concomitantly with an elevation in muscarinic M3 ACh receptor protein levels. Administration of NO-1886 attenuated the obesity-induced hypercontractility of the colonic rings of OLETF rats. Thus, intestinal contractile system would be a novel pharmacological target of the lipoprotein lipase activator NO-1886.

1. (英) Animals
2. (英) Benzamides
3. (英) Calcium
4. (英) Diabetes Mellitus, Type 2
5. (英) Gastrointestinal Motility
6. (英) Hypolipidemic Agents
7. (英) Intestinal Diseases
8. (英) Intestines
9. (英) Lipoprotein Lipase Activators
10. (英) Male
11. (英) Muscle Contraction
12. (英) Muscle, Smooth
13. (英) Myosin-Light-Chain Kinase
14. (英) Obesity
15. (英) Organophosphorus Compounds
16. (英) Peptides
17. (英) Rats
18. (英) Rats, Inbred OLETF
19. (英) Rats, Wistar

1. (英) Article.Affiliation: Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.

2. (英) Article.PublicationTypeList.PublicationType: In Vitro

3. (英) Article.PublicationTypeList.PublicationType: Journal Article

4. (英) Article.PublicationTypeList.PublicationType: Research Support, Non-U.S. Gov't